STOCK TITAN
  1. Home
  2. Sec-filings
  3. TXG
  4. [Form 4] 10x Genomics, Inc. Insider Trading Activity

10x Genomics (TXG) director sells 2,207 shares of stock

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) director Shehnaaz Suliman reported two open-market sales of Class A Common Stock on August 24, 2026. The transactions totaled 2,207 shares, consisting of 561 shares at a weighted average price of $62.7259 and 1,646 shares at a weighted average price of $63.9664. Both sales were executed under a Rule 10b5-1 trading plan adopted on March 13, 2026, and each price reflects a weighted average across multiple trades within stated price ranges.

Positive

  • None.

Negative

  • None.
Insider SULIMAN SHEHNAAZ
Role Director
Sold 2,207 shs ($140K)
Type Security Shares Price Value
Sale Class A Common Stock F1, F2 561 $62.7259 $35K
Sale Class A Common Stock F1, F3 1,646 $63.9664 $105K
Holdings After Transaction: Class A Common Stock — 29,515 shares (Direct)
Footnotes (3)
  1. F1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026.
  2. F2. This transaction was executed in multiple trades at prices ranging from $62.26 to $63.23, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. F3. This transaction was executed in multiple trades at prices ranging from $63.42 to $64.29, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Shares sold (first transaction) 561 shares of Class A Common Stock Open-market sale on August 24, 2026
Weighted average sale price (first transaction) $62.7259 per share Based on multiple trades from $62.26 to $63.23
Shares sold (second transaction) 1,646 shares of Class A Common Stock Open-market sale on August 24, 2026
Weighted average sale price (second transaction) $63.9664 per share Based on multiple trades from $63.42 to $64.29
Total shares sold 2,207 shares Sum of both reported sales on August 24, 2026
Rule 10b5-1 plan adoption date March 13, 2026 Plan under which the reported sales were effected
Rule 10b5-1 trading plan regulatory
"The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
Class A Common Stock financial
"security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

What insider activity did TXG director Shehnaaz Suliman report on this Form 4?
Shehnaaz Suliman reported two open-market sales of 10x Genomics, Inc. Class A Common Stock on August 24, 2026, totaling 2,207 shares executed at weighted average prices in the low- to mid-$60s per share.

How many TXG shares did Shehnaaz Suliman sell and at what prices?
Shehnaaz Suliman sold 561 shares at a weighted average price of $62.7259 and 1,646 shares at a weighted average price of $63.9664, for a total of 2,207 shares of 10x Genomics, Inc. Class A Common Stock.

Were the TXG insider sales by Shehnaaz Suliman under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected pursuant to Shehnaaz Suliman’s Rule 10b5-1 trading plan, which was adopted on March 13, 2026.

What price ranges applied to the TXG trades reported by Shehnaaz Suliman?
For the 561-share sale, individual trades occurred between $62.26 and $63.23. For the 1,646-share sale, trades occurred between $63.42 and $64.29. In each case, the reported price is a weighted average sale price.

Does the Form 4 state Suliman’s remaining TXG share holdings after these sales?
No. The non-derivative transaction rows list the transactions and prices, but the post-transaction share holdings field is blank, so remaining holdings are not quantified in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SULIMAN SHEHNAAZ
(Last)(First)(Middle)
C/O 10X GENOMICS, INC.
6230 STONERIDGE MALL ROAD
(Street)
PLEASANTON CALIFORNIA 94588
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock08/24/2026S(1)561D$62.7259(2)31,161D
Class A Common Stock08/24/2026S(1)1,646D$63.9664(3)29,515D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026.
2. This transaction was executed in multiple trades at prices ranging from $62.26 to $63.23, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. This transaction was executed in multiple trades at prices ranging from $63.42 to $64.29, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
/s/ Randy Wu, as Attorney-in-Fact for Shehnaaz Suliman08/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR